Targeting endocrine resistance: Is there a role for mTOR inhibition?

Clinical Breast Cancer

Volumn 10, Issue SUPPL. 3, 2010, Pages

  Sheri, Amna ^a   Martin, Lesley Ann ^b   Johnston, Stephen ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Estrogen receptor; Mammalian target of rapamycin; Metastatic breast cancer; PI3K

Indexed keywords

BIOLOGICAL MARKER; DEFOROLIMUS; ESTROGEN RECEPTOR; EVEROLIMUS; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; RIDAFOROLIMUS; TAMOXIFEN; TEMSIROLIMUS; UNCLASSIFIED DRUG;

ANOREXIA; ASTHENIA; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CELL PROLIFERATION; CELL SURVIVAL; CHOLESTEROL BLOOD LEVEL; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DYSPNEA; ENZYME INHIBITION; FATIGUE; HEADACHE; HUMAN; HYPERGLYCEMIA; LIVER FUNCTION TEST; MUCOSA INFLAMMATION; NEUTROPENIA; PNEUMONIA; PROTEIN FUNCTION; RASH; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 78649701331     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.s.016     Document Type: Article

References (60)

1. Chen D, Washbrook E, Sarwar N, et al. Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 2002; 21:4921-31.
2. Jeng MH, Yue W, Eischeid A, et al. Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Res Treat 2000; 62:167-75.
3. Stephen RL, Shaw LE, Larsen C, et al. Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem 2001; 276:40080-6.
4. Campbell RA, Bhat-Nakshatri P, Patel NM, et al. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001; 276:9817-24.
5. Martin LA, Farmer I, Johnston SR, et al. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003; 278:30458-68.
6. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96:926-35.
7. Johnston SR, Martin LA, Leary A, Head J, et al., Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer. J Steroid Biochem Mol Biol 2007; 106:180-6.
8. Johnston SR. Role of the mTOR pathway in endocrine resistant breast cancer-opportunities for novel combination strategies. Presented at: the Annual Meeting of the American Society of Clinical Oncology; May 29-June 2, 2009; Orlando, FL. ASCO Educational Book 2009; 20-8.
9. van der Heijden MS, Bernards R. Inhibition of the PI3K pathway: hope we can believe in? Clin Cancer Res 2010; 16:3094-9.
10. Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998; 10:262-7.
11. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22:2954-63.
12. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet 2005; 37:19-24.
13. Hara K, Yonezawa K, Kozlowski MT, et al. Regulation of eIF-4E BP1 phosphory-lation by mTOR. J Biol Chem 1997; 272:26457-63.
14. Chung J, Grammer TC, Lemon KP, et al. PDGF-and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 1994; 370:71-5.
15. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441:424-30.
16. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9:550-62.
17. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphory-lates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998; 273:13375-8.
18. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65:2554-9.
19. Shoman N, Klassen S, McFadden A, et al. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. Mod Pathol 2005; 18:250-9.
20. Wu G, Xing M, Mambo E, et al. Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res 2005; 7:R609-16.
21. Bachman KE, Argani P, Samuels Y, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004; 3:772-5.
22. Miron A, Varadi M, Carrasco D, et al. PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res 2010; 70:5674-8.
23. Eng C P, Sehgal SN, Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) 1984; 37:1231-7.
24. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8:249-58.
25. O'Reilly T, Vaxelaire J, Muller M. In vivo activity of RAD-001, an orally active ra-pamycin derivative, in experimental tumour models. Poc Am Assoc Cancer Research 2002; 43:71 (abstract 359).
26. Simoncini T, Hafezi-Moghadam A, Brazil D P, et al. Interaction of estrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000; 407:538-41.
27. Clark AS, West K, Streicher S, et al. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002; 1:707-17.
28. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 1995; 10:2435-46.
29. Kato S, Endoh H, Masuhiro Y, et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995; 270:1491-4.
30. Smith CL. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol Reprod 1998; 58:627-32.
31. Fan P, Wang J, Santen RJ, et al. Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res 2007; 67:1352-60.
32. Kahlert S, Nuedling S, van Eickels M, et al. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem 2000; 275:18447-53.
33. Chung YL, Sheu ML, Yang SC, et al. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 2002; 97:306-12.
34. Knowlden JM, Hutcheson IR, Jones HE, et al. Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003; 144:1032-44.
35. Cui X, Zhang P, Deng W, et al. Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer. Mol Endocrinol 2003; 17:575-88.
36. Pancholi S, Lykkesfeldt AE, Hilmi C, et al. ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr Relat Cancer 2008; 15:985-1002.
37. Boulay A, Rudloff J, Ye J, et al. Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 2005; 11:5319-28.
38. DeGraffenried LA, Friedrichs WE, Russell DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 2004; 10:8059-67.
39. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22:2336-47.
40. O'Donnell A, Faivre S, Burris HA 3rd, et al. Phase I pharmacokinetic and pharma-codynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008; 26:1588-95.
41. Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 2005; 23:5314-22.
42. Awada A, Cardoso F, Fontaine C, et al. The oral mTOR inhibitor RAD001 (evero-limus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics. Eur J Cancer 2008; 44:84-91.
43. Baselga J, Fumoleau P, Gil M, et al. Phase II 3-arm study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advance or metastatic breast cancer: preliminary results. J Clin Oncol 2004; 22(14 suppl): (abstract 544).
44. Baselga J, Roché H, Fumoleau P, et al. Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combination with temsirolimus: a randomized, 3arm phase 2 study. Breast Cancer Res Treat 2005; 94(1 suppl): (abstract 1068).
45. Chow LW, Sun Y, Jassem J, et al, Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006; 100(1 suppl): (abstract 6091).
46. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6:729-34.
47. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66:1500-8.
48. Sun SY, Rosenberg LM, Wang X, et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65:7052-8.
49. Tabernero J, Rojo F, Calvo E, et al. Dose-and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26:1603-10.
50. Sarbassov DD, Guertin DA, Ali SM, et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-101.
51. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6:1122-8.
52. Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoad-juvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009; 27:2630-7.
53. Barbareschi M, Buttitta F, Felicioni L, et al. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 2007; 13:6064-9.
54. Ellis MJ, Lin L, Crowder R, et al. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 2010; 119:379-90.
55. Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008; 100:1380-8.
56. Loi S, Haibe-Kains B, Majjaj S, et al. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 2010; 107:10208-13.
57. Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27:5538-46.
58. Yao JC, Phan AT, Change DZ, et al. Phase II study of RAD001 (everolimus) and depot octreotide (Sandostatin LAR) in patient with advanced low grade neuroendo-crine carcinoma (LGNET). J Clin Oncol 2006; 24(18 suppl):189s (abstract 4042).
59. Di Cosimo S, Bendell JC, Cervantes-Ruiperez, A. et al. A phase 1 study of the oral mTOR inhibitor ridaforolimus in combination with the IGF-1R antibody in patients with advanced solid tumours. J Clin Oncol 2010; 28(15 suppl):235s (abstract 3008).
60. Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68:8022-30.